II 

109TH CONGRESS 

1ST SESSION S. 1930 

To expand the research, prevention, and awareness activities of the National 

Institute of Diabetes and Digestive and Kidney Diseases and the Centers 

for Disease Control and Prevention with respect to inflammatory bowel 

disease. 

IN THE SENATE OF THE UNITED STATES 

OCTOBER 27, 2005 

Mr. REID (for himself and Mr. COCHRAN) introduced the following bill; which 

was read twice and referred to the Committee on Health, Education, 

Labor, and Pensions 

A BILL 

To expand the research, prevention, and awareness activities 

of the National Institute of Diabetes and Digestive and 

Kidney Diseases and the Centers for Disease Control 

and Prevention with respect to inflammatory bowel disease. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Inflammatory Bowel 

5 Disease Research Act’’. 

6 SEC. 2. FINDINGS. 

7 The Congress finds as follows: 
2 

•S 1930 IS 

1 (1) Crohn’s disease and ulcerative colitis are se2 rious inflammatory diseases of the gastrointestinal 

3 tract. 

4 (2) Crohn’s disease may occur in any section of 

5 the gastrointestinal tract but is predominately found 

6 in the lower part of the small intestine and the large 

7 intestine. Ulcerative colitis is characterized by in8 flammation and ulceration of the innermost lining of 

9 the colon. Complete removal of the colon in patients 

10 with ulcerative colitis can potentially alleviate and 

11 cure symptoms. 

12 (3) Because Crohn’s disease and ulcerative coli13 tis behave similarly, they are collectively known as 

14 inflammatory bowel disease. Both diseases present a 

15 variety of symptoms, including severe diarrhea; ab16 dominal pain with cramps; fever; and rectal bleeding. 

17 There is no known cause of inflammatory bowel dis18 ease, or medical cure. 

19 (4) It is estimated that up to 1,400,000 people 

20 in the United States suffer from inflammatory bowel 

21 disease, 30 percent of whom are diagnosed during 

22 their childhood years. 

23 (5) Children with inflammatory bowel disease 

24 miss school activities because of bloody diarrhea and 

25 abdominal pain, and many adults who had onset of 
3 

•S 1930 IS 

1 inflammatory bowel disease as children had delayed 

2 puberty and impaired growth and have never 

3 reached their full genetic growth potential. 

4 (6) Inflammatory bowel disease patients are at 

5 high risk for developing colorectal cancer. 

6 (7) The total annual medical costs for inflam7 matory bowel disease patients is estimated at more 

8 than $2,000,000,000. 

9 SEC. 3. NATIONAL INSTITUTE OF DIABETES AND DIGES10 TIVE AND KIDNEY DISEASES; INFLAMMATORY 

11 BOWEL DISEASE RESEARCH EXPANSION. 

12 (a) IN GENERAL.—The Director of the National In13 stitute of Diabetes and Digestive and Kidney Diseases 

14 shall expand, intensify, and coordinate the activities of the 

15 Institute with respect to research on inflammatory bowel 

16 disease, with particular emphasis on the following areas: 

17 (1) Genetic research on susceptibility for in18 flammatory bowel disease, including the interaction 

19 of genetic and environmental factors in the develop20 ment of the disease. 

21 (2) Research targeted to increase knowledge 

22 about the causes and complications of inflammatory 

23 bowel disease in children. 

24 (3) Animal model research on inflammatory 

25 bowel disease, including genetics in animals. 
4 

•S 1930 IS 

1 (4) Clinical inflammatory bowel disease re2 search, including clinical studies and treatment 

3 trials. 

4 (5) Expansion of the Institute’s Inflammatory 

5 Bowel Disease Centers program with a focus on pe6 diatric research. 

7 (6) Other research initiatives identified by the 

8 scientific document entitled ‘‘Challenges in Inflam9 matory Bowel Disease’’ and the research agenda for 

10 pediatric gastroenterology, hepatology and nutrition 

11 entitled ‘‘Chronic Inflammatory Bowel Disease’’. 

12 (b) AUTHORIZATION OF APPROPRIATIONS.— 

13 (1) IN GENERAL.—For the purpose of carrying 

14 out subsection (a), there are authorized to be appro15 priated $75,000,000 for fiscal year 2006, 

16 $85,000,000 for fiscal year 2007, and $100,000,000 

17 for fiscal year 2008. 

18 (2) RESERVATION.—Of the amounts authorized 

19 to be appropriated under paragraph (1), not more 

20 than 20 percent shall be reserved for the training of 

21 qualified health professionals in biomedical research 

22 focused on inflammatory bowel disease, including pe23 diatric investigators. 
5 

•S 1930 IS 

1 SEC. 4. CENTERS FOR DISEASE CONTROL AND PREVEN2 TION; NATIONAL INFLAMMATORY BOWEL DIS3 EASE ACTION PLAN. 

4 (a) IN GENERAL.— 

5 (1) PREPARATION OF PLAN.—The Director of 

6 the Centers for Disease Control and Prevention, in 

7 consultation with the inflammatory bowel disease 

8 community, shall prepare a comprehensive plan to 

9 address the burden of inflammatory bowel disease in 

10 both adult and pediatric populations (which plan 

11 shall be designated by the Director as the ‘‘National 

12 Inflammatory Bowel Disease Action Plan’’). 

13 (2) REPORT TO CONGRESS.—Not later than 12 

14 months after the date of the enactment of this Act, 

15 the Director of the Centers for Disease Control and 

16 Prevention shall submit the Plan referred to in para17 graph (1) to the Committee on Energy and Com18 merce and the Committee on Appropriations in the 

19 House of Representatives and to the Committee on 

20 Health, Education, Labor and Pensions and the 

21 Committee on Appropriations in the Senate. 

22 (b) CONTENT.— 

23 (1) IN GENERAL.—The National Inflammatory 

24 Bowel Disease Action Plan shall address strategies 

25 for determining the true prevalence of inflammatory 

26 bowel disease in the United States, and the unique 
6 

•S 1930 IS 

1 demographic characteristics of the patient commu2 nity through the expansion of appropriate epidemio3 logical activities. 

4 (2) CERTAIN REQUIREMENTS.—The Plan re5 ferred to in paragraph (1) shall— 

6 (A) focus on strategies for increasing 

7 awareness about inflammatory bowel disease 

8 within the general public and the health care 

9 community in order to facilitate more timely 

10 and accurate diagnoses; and 

11 (B) address mechanisms designed to pre12 vent the progression of the disease and the de13 velopment of complications, such as colorectal 

14 cancer, and other strategies and activities as 

15 deemed appropriate. 

16 (c) AUTHORIZATION OF APPROPRIATIONS.—For the 

17 purpose of carrying out this section, there is authorized 

18 to be appropriated such sums as may be necessary for fis19 cal year 2006. 

Æ